14,434 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by Marshall Wace LLP

Marshall Wace LLP purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 14,434 shares of the company's stock, valued at approximately $4,795,000.

A number of other institutional investors have also made changes to their positions in the stock. R Squared Ltd bought a new position in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of Medpace during the fourth quarter worth about $31,000. Jones Financial Companies Lllp lifted its holdings in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Lindbrook Capital LLC grew its position in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the period. Finally, Assetmark Inc. increased its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MEDP. Robert W. Baird reduced their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Leerink Partners assumed coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Leerink Partnrs upgraded Medpace to a "hold" rating in a report on Monday, March 24th. Finally, William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $349.30.

Medpace Trading Down 0.1 %

Shares of Medpace stock traded down $0.37 on Monday, reaching $298.18. 390,361 shares of the company were exchanged, compared to its average volume of 340,141. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77. The company has a 50-day moving average of $313.79 and a 200 day moving average of $331.60. The company has a market capitalization of $8.57 billion, a price-to-earnings ratio of 23.61, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same quarter last year, the company posted $3.20 earnings per share. Analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.